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ABSTRACT
Adeno-associated virus (AAV) is a dependent virus of the family Parvoviridae. The gene expression and replication of AAV and
derived recombinant AAV (rAAV) vectors are severely limited (>10-fold) by the cellular DNA damage-sensing complex made up
of Mre11, Rad50, and Nbs1 (MRN). The AAV genome does not encode the means to circumvent this block to productive infec-
tion but relies on coinfecting helper virus to do so. Using adenovirus helper proteins E1B55k and E4orf6, which enhance the
transduction of AAV via degradation of MRN, we investigated the mechanism through which this DNA damage complex inhibits
gene expression from rAAV. We tested the substrate specificity of inhibition and the contribution of different functions of the
MRN complex. Our results demonstrate that both single- and double-stranded rAAV vectors are inhibited by MRN, which is in
contrast to the predominant model that inhibition is the result of a block to second-strand synthesis. Exploring the contribution
of known functions of MRN, we found that inhibition of rAAV does not require downstream DNA damage response factors, in-
cluding signaling kinases ATM and ATR. The nuclease domain of Mre11 appears to play only a minor role in inhibition, while
the DNA binding domain makes a greater contribution. Additionally, mutation of the inverted terminal repeat of the rAAV ge-
nome, which has been proposed to be the signal for interaction with MRN, is tolerated by the mechanism of inhibition. These
results articulate a model of inhibition of gene expression in which physical interaction is more important than enzymatic activ-
ity and several key downstream damage repair factors are dispensable.
IMPORTANCE
Many viruses modulate the host DNA damage response (DDR) in order to create a cellular environment permissive for infection.
The MRN complex is a primary sensor of damage in the cell but also responds to invading viral genomes, often posing a block to
infection. AAV is greatly inhibited by MRN and dependent on coinfecting helper virus, such as adenovirus, to remove this factor.
Currently, the mechanism through which MRN inhibits AAV and other viruses is poorly understood. Our results reform the
predominant model that inhibition of rAAV by MRN is due to limiting second-strand DNA synthesis. Instead, a novel mecha-
nism of inhibition of gene expression independent of a block in rAAV DNA synthesis or downstream damage factors is indi-
cated. These findings have clear implications for understanding this restriction to transduction of AAV and rAAV vectors, which
have high therapeutic relevance and likely translate to other viruses that must navigate the DDR.
Adeno-associated virus (AAV) is a member of the genus De-pendovirus within the family Parvoviridae. The virion is small
(diameter, 20 nm) and consists of a protein nucleocapsid con-
taining a single-stranded DNA (ssDNA) genome of 4.7 kb. The
genome carries inverted terminal repeat (ITR) sequences at both
ends, which self-anneal to form a T-shaped secondary structure
(1, 2). Formation of this structure provides the 3=OH for second-
strand DNA synthesis, as well as the signal for genome packaging.
Flanking ITRs are the only feature required in cis for replication
and production of the virus. This property is exploited in recom-
binant AAV (rAAV) vectors, in which the coding region of the
genome is replaced with a transgene expression cassette (3). The
AAV genome carries two genes encoding replication (Rep) and
capsid (Cap) proteins (4). Both are required for replication and
packaging of AAV and are provided in trans for production of
rAAV vectors. However, these proteins are not sufficient. Wild-
type (wt) AAV and rAAV are dependent upon helper virus and
host cell proteins for creation of a permissive cellular environment
and DNA synthesis machinery, respectively (5, 6).
Establishment of a permissive cellular environment for expres-
sion and replication of AAV requires mediation of the cellular
DNA damage response (DDR). DDR signaling and repair path-
ways normally function in maintenance of the cellular genome.
However, these pathways can be activated during viral infection,
adopting auxiliary, often antagonistic roles when confronted with
foreign genetic material (7, 8). The AAV genome does not encode
a mechanism to mediate the DDR but requires helper virus to
accomplish this. In the absence of helper virus, wt AAV and rAAV
provoke only minor damage signaling in the form of phosphory-
lation of -H2AX (9, 10). During such infections, gene expression
is muted and the virus may circularize or integrate into the host
genome, as is the case with wt AAV in the presence of Rep pro-
teins, resulting in latency (11, 12). Coinfection with AAV and the
adenovirus (Ad) helper (i.e., productive infection) produces ro-
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bust DDR signaling, involving activation of the kinases DNA-de-
pendent protein kinase (DNA-PK) and ATM and downstream
targets, including Chk1 and Chk2 (10, 13). Activation of these
pathways is provoked by AAV genome replication but appears to
be regulated in a manner that benefits the virus. The activity of
DNA-PK has been demonstrated to enhance AAV replication,
possibly via a role in processing of the ITRs (14, 15). In contrast,
the complex made up of Mre11, Rad50, and Nbs1 (MRN) restricts
AAV replication and is downregulated by Ad proteins during
coinfection (16).
MRN plays a critical role in the permissiveness of a cell to
transduction by AAV and other viral and nonviral pathogens (7,
17). This complex normally functions as a sensor of DNA damage
in the cell and participates in the homologous recombination
(HR) and nonhomologous end joining (NHEJ) pathways of repair
(18–21). MRN accumulates at foci on cellular DNA within min-
utes after insult (22, 23). It then initiates damage signaling involv-
ing activation of ATM and ATR kinases (24–26). During infection
with AAV, MRN is recruited to the viral genome shortly after
introduction and dramatically limits the activity of the virus (27).
Coprecipitation from the cell lysate and interaction of purified
Mre11 and Nbs1 proteins with an oligonucleotide representing
the viral ITR in vitro suggest a direct interaction with the viral
genome, possibly via the terminal hairpin structures (16, 27).
Knockdown of proteins of the MRN complex with short hairpin
RNA (Rad50) or small interfering RNA (Nbs1) leads to enhance-
ment of virus, and fibroblasts deficient for Mre11 are highly per-
missible to transduction (16, 27). Additionally, the permissiveness
of muscle cells to rAAV in vivo correlates with the loss of MRN
during differentiation (28). During productive infection, coin-
fecting helper viruses remove this block to infection. Herpes sim-
plex virus (HSV) utilizes MRN during replication and recruits this
complex to its genome (29–31). This may have the effect of se-
questering MRN, thus relieving inhibition and contributing to the
enhancement of AAV observed with HSV. In contrast, Ad, like
AAV, is inhibited by MRN and expresses mechanisms to remove
this barrier. Early proteins E1B55k and E4orf6 form an E3-like
ubiquitin ligase complex and target MRN for degradation (32). In
a redundant mechanism, early protein E4orf3 relocalizes the com-
plex to the cytoplasm, away from the viral genome (33, 34). The
dependence of AAV on helper viruses to remove MRN for pro-
ductive infection indicates the severity of the inhibitory effect.
However, the mechanism of inhibition of AAV by MRN is not well
understood.
Here, we investigate the mechanism of MRN inhibition of gene
expression from rAAV genomes, in which the viral promoters and
genes have been replaced with a reporter gene expression cassette.
Previous studies have found that the degradation of MRN by
E1B55k/E4orf6 leads to increased second-strand DNA synthesis
for AAV (35, 36). This result has been interpreted to suggest that
MRN blocks completion of the genome, which has been proposed
to be the mechanism of inhibition. Using Ad proteins E1B55k and
E4orf6 as a tool to track inhibition by MRN, we tested this model
and found that double-stranded rAAV vectors, which do not re-
quire second-strand DNA synthesis for gene expression, are en-
hanced in a manner similar to that for single-stranded vectors.
Probing further into the nature of this mechanism, we investi-
gated the contribution of downstream DNA damage signaling and
repair factors and the specific activities of Mre11. Analysis of cell
lines deficient for DDR factors downstream of MRN indicates that
key signaling kinases ATM and ATR, as well as factors important
for the HR and NHEJ repair pathways, are not required for inhi-
bition. Additionally, the contribution of the nuclease activity of
Mre11 appears to be minor. Instead, our findings implicate a role
for the DNA binding domain of Mre11. In an effort to understand
the importance of the ITR to this interaction, mutation of this
feature was performed and indicates that sequence and structure
may already be optimized to limit the effect of MRN. Together,
these results suggest that a direct interaction may be more impor-
tant to the mechanism of inhibition of rAAV than the enzymatic
or signaling activities of MRN.
MATERIALS AND METHODS
Plasmids. Plasmids pXR2 (AAV serotype 2 [AAV2] Rep/Cap donor) and
pXX6-80 (adenovirus protein donor) have been described previously (37,
38). Plasmids pTR2-CMV-eGFP-Neo, pTR2-CMV-Luc, and pTR2-CBA-
Luc harbor a single-stranded AAV genome flanked by serotype 2 ITRs and
contain either the human cytomegalovirus (CMV) major immediate early
or chicken -actin (CBA) promoter driving the expression of either the
enhanced green fluorescent protein (eGFP) or luciferase transgene (39–
41). The Ad serotype 5 (Ad5) E1B55k gene was amplified from the
genomic DNA of HEK293 cells, which carry the E1 region of Ad5, with
primers Ad5 SalI/AgeI 2019-2042 (5=-GACGTCGACCGGTATGGAG
CGAAGAAACCCATCTGAG-3=) and Ad5 NotI 3479-3509 (5=-CCGCG
GCCGCTCAATCTGTATCTTCATCGCTAGAGCCAAAC-3=). The PCR
product was ligated into the plasmid pTR2-CMV-eGFP-Neo using the
AgeI and NotI restriction sites to produce pTR2-CMV-E1B55k-Neo.
Plasmid pdsEMBLgfp4 harbors a self-complementary AAV (scAAV) vec-
tor genome flanked by one wt and one defective serotype 2 ITR and con-
tains the CMV promoter driving the expression of eGFP (a kind gift from
X. Xiao). Plasmid pdsEMBL-CMV-E4orf6 (pMH210) was constructed by
BamHI excision of the adenovirus E4orf6-coding sequence from pCMV-
E4orf6 (a kind gift from P. Hearing), treatment with the Klenow fragment
to blunt the ends, and ligation into blunt-ended AgeI and NotI sites of
pdsEMBLgfp4 (42). Plasmids pDD2-eGFP, pDD5-eGFP, pDD52SNS-
eGFP, and pDD25NS-eGFP have been described previously and consist
of a single wild-type or mutant ITR in DD form inserted along with a
CMV-eGFP expression cassette into the pUC18 backbone (43, 44). Plas-
mid pTRSn-CMV-eGFP was generated by substitution of a CMV-eGFP
expression cassette, flanked by PstI and PciI restriction sites, for the ma-
jority of the genome in the snake AAV construct pSAAV (a kind gift from
Peter Tijssen) via compatible PstI and NcoI restriction sites (45). A donor
plasmid for expression of the snake AAV Rep protein was generated in
order to produce the TRSn-CMV-eGFP vector. The snake AAV Rep gene
was amplified from pSAAV and fused with the AAV serotype 2 Cap gene
(with the AAV2 Cap replacing the snake Cap sequence) by overlap exten-
sion PCR. This fragment was then substituted for the wt AAV2 Rep gene
sequence in pXR2 via SacI and SacII restriction sites.
Production of rAAV. Recombinant AAV vectors were generated us-
ing HEK293 cells grown under serum-free suspension conditions in
shaker flasks (J. Grieger et al., unpublished data). The suspended HEK293
cells were transfected using polyethyleneimine (PEI; Polysciences), plas-
mids pXX680 and pXR2, and a vector genome plasmid. At 48 h posttrans-
fection, cell cultures were collected into 500-ml polypropylene conical
tubes (Corning) and centrifuged at 655  g for 10 min using a Sorvall
RC3C plus centrifuge and H6000A rotor. The supernatant was discarded,
and the cells were suspended in a total volume of 7 ml with H2O, soni-
cated, and purified over a discontinuous iodixanol gradient, followed by
passage through a heparin column, as described previously (46). Individ-
ual vector preparations were compared against plasmid and/or known
virus standards by quantitative PCR to determine the number of vector
genomes (vg) per ml.
Vectors packaging self-complementary CMV (scCMV)-eGFP with
the AAV serotype 2 capsid and single-stranded CMV (ssCMV)-eGFP with
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the AAV serotype 1, 3, 4, 5, 6, 8, or 9 capsid were obtained from the
University of North Carolina Vector Core Facility. The Ad5-CMV-Cre
vector was obtained from the Baylor University Vector Development Lab.
Cell lines and culturing. All cell lines used in this study were cultured
at 37°C in 5% CO2 and grown in a base medium of Dulbecco modified
Eagle medium (DMEM; 4.5 g/liter glucose, L-glutamine, sodium pyru-
vate; Cellgro) supplemented with 10% fetal bovine serum (FBS; Invitro-
gen), 100 U/ml penicillin, and 100 g/ml streptomycin (Gibco), modified
as indicated below. The human cell lines used in this study were obtained
from the Coriell Institute (Camden, NJ), unless otherwise indicated (Ta-
ble 1) (47). Normal human fibroblasts (NHFs) and AT (with a mutation
in ATM) and ATLD2 (with a mutation in Mre11) human fibroblasts im-
mortalized with human telomerase reverse transcriptase (h-TERT) were
obtained from W. Kaufmann (University of North Carolina). HeLa and
M059J (a glioblastoma with a mutation in the DNA-PK catalytic subunit
[DNA-PKcs]) cells, as well as NHFs and AT and ATLD2 human fibro-
blasts immortalized with h-TERT, were cultured in the base medium (48).
Human fibroblast cell line AG00780 (with a mutation in Werner’s syn-
drome helicase [WRN]) was maintained in base medium modified to
contain 1 nonessential amino acids (NEAA; Gibco). Human fibroblast
cell lines AG06040 (with a mutation in Bloom’s syndrome helicase
[BLM]) and AG05012 (with a mutation in CSA) were maintained in base
medium modified to contain 15% FBS and 1 NEAA. Human osteosar-
coma cell line GK41 (which conditionally expresses dominant negative
ATR) was maintained in base medium modified to contain 200 g/ml
G418 and 200 g/ml hygromycin B (49). Expression of ATR kinase dead
(ATR-kd) was induced by addition of doxycycline to 1 g/ml to the cell
culture medium beginning 48 h prior to treatment with vectors.
Mouse embryonic fibroblast (MEF) lines with mutations in the Mre11
gene were generously provided by other investigators. MEFs carrying the
ATLD1 mutation (a kind gift of J. H. Petrini) and MEFs carrying an
arginine-to-lysine (RK) mutation (Mre11RK/RK; a kind gift of S. Richard),
as well as their isogenic wild-type controls, wt and Mre11/, respectively,
were maintained in the base medium described above (50, 51). MEFs carry-
ing an H129N substitution mutation in the presence of a conditional wt
(Cond) allele, as well as deficient and wt controls (Mre11Cond/H129N,
Mre11Cond/, Mre11Cond/; kind gifts of D. Ferguson) were maintained
in base medium modified to contain 10 mM HEPES (Cellgro) and 1
NEAA (52).
Transfection and transductions. In all experiments, cells were counted
on a ViCell cell counter (Beckman Coulter) and plated at a known concen-
tration.
For transfection, plasmid DNA (50 ng to 1 g) was brought to 200 l
with DMEM (without FBS, penicillin, or streptomycin), mixed with 5 to
10 l of PEI (1 mg/ml) by vortexing, and incubated at ambient tempera-
ture (25°C) for 10 min. This solution was added directly to the growth
medium on plated cells at 37°C. After 3 h, medium containing the trans-
fection solution was replaced with growth medium and the cells were
cultured until collection at 24 h.
For transduction, viral vectors were diluted in fresh growth medium
and exchanged for growth medium on plated cells. AAV vectors were
diluted to 1,000 to 20,000 vg/cell, depending on the cell line, and the Ad
vector was diluted to 2,000 or 8,000 particles/cell. Transduction me-
dium was kept on the cells for 6 h, after which it was replaced with growth
medium. Cells were pretreated with ssCMV-E1B55k and scCMV-E4orf6
in a ratio of 1:1 to 1:4 (optimized with each preparation of vector) or an
equal concentration of ssCMV-Luc or ssCBA-Luc. Medium containing
reporter vector ssCMV-GFP or scCMV-GFP was then added to the cells
18 h after the pretreatment vectors had been removed. This transduction
medium was exchanged for growth medium after 6 h. Cells were collected
at 24 h after treatment with the reporter vector (Fig. 1B).
Green fluorescent protein (GFP) fluorescence was measured by flow
cytometry on a Cyan ADP flow cytometer (Beckman Coulter). The
threshold for a positive signal was defined for each cell line as the level of
fluorescence above which 0.5% of untreated cells are counted. The con-
centration (vg/cell) of GFP reporter vector used with each cell line was
adjusted to produce 1 to 10% GFP-positive cells in luciferase-treated
controls. An exception to this was the transduction of HeLa cells with the
ssCMV-GFP vector encapsidated by different serotype nucleocapsids,
several of which transduced 	1% of cultured cells in the absence of
E1B55k/E4orf6 (see Fig. 3A).
Antibodies and immunoblotting. Protein levels in total cell lysate
were detected by immunoblotting. Cells were lysed with 100 l of radio-
immunoprecipitation assay buffer (25 mM Tris-HCl, pH 7.6, 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS). Lysate was mixed
with 1 l DNase, and this mixture was brought to 1 with Halt protease
inhibitor cocktail (Thermo Scientific). Equal fractions of the samples were
mixed with 4 sample loading buffer, boiled for 5 to 10 min, resolved by
SDS-PAGE, and transferred to a nitrocellulose membrane. Membranes
were blocked in 5% bovine serum albumin (BSA) for 1 h at ambient
temperature. Adenovirus proteins were detected with the primary anti-
bodies mouse (Ms) anti-E1B55k (2A6; a kind gift from P. Branton) at
1:5,000 and rabbit (Rb) anti-E4orf6 (a kind gift from G. Ketner) at
1:1,000. Cellular proteins were detected with the primary antibodies Rb
anti-Mre11 (catalog number 4895; Cell Signaling Technology) at 1:1,000,
Rb anti-Nbs1 (catalog number NB100-143; Novus Biologicals) at 1:1,000,
and Ms anti--actin (catalog number 8226; Abcam) at 1:5,000. Secondary
anti-Ms and anti-Rb antibodies conjugated with horseradish peroxidase
(HRP) were used at 1:20,000, and goat anti-Ms or anti-Rb antibodies
conjugated with IRDye800 or IRDye680 (catalog numbers 926-68070,
926-32210, 926-68021, and 926-32211; LiCor) were used at 1:10,000. An-
tibody incubations were performed in 1% BSA for 1 h at ambient temper-
ature. Membranes were washed 5 times with TBS-T (50 mM Tris, 150 mM
NaCl, 0.05% Tween 20) after incubation with antibody. For visualization
of HRP activity, membranes were treated with SuperSignal West Pico
chemiluminescent substrate reagents per the manufacturer’s instruction
(Thermo Scientific). For visualization of the IRDye fluorophores, the
membranes were dried and imaged on an Odyssey scanner (LiCor).
Southern blotting. Viral DNA was isolated from cells by a modified
Hirt extraction method. Cells were suspended in 259 l Hirt solution (10
mM Tris-HCl, pH 7.5, 10 mM EDTA). This solution was brought to 0.6%
SDS and 1 M NaCl in a total volume of 350 l. The sample was then mixed
and incubated at 4°C for 24 h. Precipitated material was pelleted at
16,000  g for 20 min at 4°C. The supernatant was extracted with 350 l
phenol-chloroform-isoamyl alcohol (25:24:1). DNA was precipitated
from the aqueous layer after addition of 1 g glycogen, NaCl to a final
concentration of 0.2 M, and 2.2 volumes of ethanol (EtOH). After pel-
TABLE 1 Cell lines used in this study
Species and cell line Mutated protein Source (reference)
Human
NHF-hTERT None W. K. Kaufmann (48)
ATLD2-hTERT Mre11 W. K. Kaufmann (48)
AT-hTERT ATM W. K. Kaufmann (48)
GK41 ATR Coriell Institute (49, 60–63)
AG06040 BLM Coriell Institute (49, 60–63)
AG00780 WRN Coriell Institute (49, 60–63)
M059J DNA-PKcs Coriell Institute (49, 60–63)
AG05012 CSA Coriell Institute (49, 60–63)
Mouse
wt None J. H. Petrini (50, 64)
ATLD1 Mre11 J. H. Petrini (50, 64)
Mre11/ None S. Richard (51)
Mre11RK/RK Mre11 GAR domain S. Richard (51)
Mre11Cond/ None D. O. Ferguson (52)
Mre11Cond/ Mre11 knockout D. O. Ferguson (52)
MrellCond/H129N Mre11 H129N D. O. Ferguson (52)
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leting at 16,000  g for 10 min, the DNA was washed with 70% EtOH and
suspended in 20 l TE (Tris-EDTA) buffer. The resulting samples were
electrophoresed through a 1% agarose gel in TAE buffer (40 mM Tris-
acetate, 1 mM EDTA, pH 8.3). The gels were soaked for 15 min in 0.4 N
NaOH, 1 M NaCl and transferred to a Hybond-XL membrane (GE
Healthcare). The membranes were rinsed in H2O and then cross-linked
with UV. Prehybridization blocking was performed in Church buffer (0.5
M NaPO4, pH 7.5, 1% BSA, 1 mM EDTA, 7% SDS) for 30 min at 65°C.
Radiolabeled probe was synthesized with a Random Primed DNA labeling
kit (Roche) using the AgeI-NotI restriction fragment of pTR2-CMV-
GFP-Neo containing only the GFP gene as the template. Purified probe
was mixed with 1 mg salmon sperm DNA (Invitrogen), and the mixture
was boiled for 5 min prior to addition to the membrane and incubation at
65°C for 24 h. The membrane was then washed 3 times in high-salt
solution (2 SSC [1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate],
0.1% SDS) and once in low-salt solution (0.1 SSC, 0.1% SDS) before
exposure to a storage phosphor screen and detection on a Typhoon
scanner (GE Healthcare). Densitometric quantitation was performed
with ImageQuant software (GE Healthcare).
Fluorescence microscopy. For visualization of the vector, HeLa cells
were grown on glass coverslips in 12-well plates. Transduction was con-
ducted as described above. Cells received the E1B55k/E4orf6- or the lu-
ciferase-expressing vector at 2,000 vg/cell, and the medium was changed
at 6 h. Highly pure Cy5-labeled ssTR2-CMV-GFP-Neo vector (kind gift
from P. Xiao) was delivered to the cells 18 h after the pretreatment me-
dium was removed (53). At 6 h postransduction with labeled vector, the
coverslips were washed three times with 1 phosphate-buffered saline
(PBS), incubated with freshly prepared 2% paraformaldehyde for 15 min,
washed three times in 1 PBS again, and mounted onto slides with Pro-
Long Gold antifade reagent with DAPI (4=,6-diamidino-2-phenylindole;
Molecular Probes). Cells were imaged on an Odyssey IX81 inverted light
microscope.
Statistical analysis. Statistical comparisons were performed using the
Wilcoxon signed-rank test between paired data samples. Paired data sam-
ples were defined as samples treated, isolated, and analyzed at the same
time.
RESULTS
Mobilization of E1B55k/E4orf6 helper function in rAAV vec-
tors. Ad proteins E1B55k and E4orf6 are required for productive
infection with AAV during coinfection of these viruses and suffi-
cient for enhancement of gene expression from rAAV vectors.
These functions have been linked to degradation of the cellular
MRN complex, which poses a severe block to AAV transduction
(16). We generated rAAV vectors carrying E1B55k and E4orf6 and
rAAV vectors carrying ssCMV-E1B55k and scCMV-E4orf6 in or-
der to facilitate the expression of these proteins in cell lines refrac-
tory to other methods of gene transfer (i.e., transfection of plas-
mid DNA or transduction with lentiviral vectors). Expression of
the E1B55k and E4orf6 proteins from these vectors was detected in
HeLa cells 24 h after transduction with 1,000 vg/cell by immuno-
blotting (Fig. 1A). Enhancement of secondary transduction with
rAAV was tested for using a pulse infection approach (Fig. 1B).
Cells were pretreated with ssCMV-E1B55k/scCMV-E4orf6 or a
negative-control vector expressing luciferase for 6 h, after which
the medium was replaced. Cells were secondarily treated with the
ssCMV-GFP vector 18 h later, and the medium was again replaced
after 6 h. This allowed expression of E1B55k/E4orf6 for up to 24 h
prior to introduction of the reporter vector. In HeLa cells, pre-
treatment vectors were delivered at 2,000 vg/cell (total) and the
reporter vector was delivered at 1,000 vg/cell. Similar to previous
reports, enhancement of gene expression was observed (Fig. 1C).
The percentage of cells that scored positive for GFP by flow cy-
tometry was increased 6-fold (P 	 0.05). To verify that this
enhancement was specific for rAAV vector transduction and not
generalized to the CMV promoter or other features of the expres-
sion cassette, a control experiment was performed with the trans-
fection of plasmid DNA. No increase in expression was observed
with pDD2-CMV-GFP, which carries the same expression cassette
as ssCMV-GFP (Fig. 1D). Thus, this method reproduces the
helper function of E1B55k/E4orf6 on AAV transduction. Addi-
FIG 1 Mobilization of E1B55k/E4orf6 enhancement of AAV gene expression. (A) Expression of Ad proteins E1B55k and E4orf6 from AAV vectors in HeLa cells.
Cells received 1,000 vg/cell of the scCMV-E4orf6 or ssCMV-E1B55k vector. Expression of protein was detected in total cell lysate by SDS-PAGE and immuno-
blotting. The level of -actin was evaluated as a loading control. (B) Schematic of pulse infection method used to assess the effect of E1B55k/E4orf6 on gene
expression from a GFP reporter vector. m.c., medium change. (C) Visualization of GFP expression in transduced cell cultures and quantification of the
percentage of cells positive for GFP by flow cytometry. HeLa cells were pretreated to express E1B55k/E4orf6 or luciferase (a total of 2,000 vg/cell) and secondarily
transduced with an ssCMV-GFP reporter plasmid (1,000 vg/cell). After 24 h, cells were collected and GFP expression was quantified by flow cytometry. (D) Effect
of E1B55k/E4orf6 on transfected plasmid DNA. Cells were pretreated with E1B55k/E4orf6 or luciferase as described in the legend to panel C but secondarily
transfected with a plasmid DNA carrying the CMV-GFP expression cassette. Again, GFP expression was quantified by flow cytometry. Error bars represent
standard deviations. *, P 	 0.05; n.s., not significant.
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tionally, the two-vector approach is efficient enough to affect
25% of HeLa cells, which is sufficient to track the effect.
Both single-stranded and double-stranded forms of rAAV
are inhibited by MRN. One rationale for mobilizing E1B55k and
E4orf6 in rAAV vectors was to study the effect of these proteins in
cell lines refractory to other methods of gene transfer. For exam-
ple, the ability to transduce fibroblasts opens the door to track the
enhancement of rAAV in a variety of genetic backgrounds, includ-
ing patient- and mouse model-derived cell lines. To assess the
E1B55k/E4orf6 helper function in such cell lines, we repeated the
experimental format performed with HeLa cells outlined in Fig. 1
with an NHF line which has been immortalized with h-TERT (48).
A pretreatment vector dose of 20,000 vg/cell and a secondary
treatment dose of 10,000 vg/cell were used and produced 2 to
8% GFP-positive cells among control treated cells. Consistent
with previous reports, upon delivery of E1B55k/E4orf6, we ob-
served the depletion of the Mre11 and Nbs1proteins of the MRN
complex at 24 h postransduction (Fig. 2A). Mre11 and Nbs1 pro-
tein levels were not completely degraded, but this was expected
due to the efficiency of transduction of this two-vector approach.
As was observed with HeLa cells, transduction of ssCMV-GFP was
dramatically enhanced in cells expressing E1B55k/E4orf6 com-
pared with the level of transduction in those expressing luciferase
(Fig. 2B). At 24 h postransduction, the percentage of cells positive
for GFP was increased 
10-fold (P 	 0.05), as measured by flow
cytometry, and the effect reached 
50% of cells. Enhancement
was not observed in the ATLD2 cell line, which has a mutation in
Mre11. ATLD2 cells carry a premature stop codon in the gene
encoding Mre11 and express a truncated form of the protein (48,
54). Mre11, Rad50, and Nbs1 protein levels and MRN complex
formation are reduced in this cell line. The percentage of cells
positive for GFP was increased among control-treated ATLD2
cells relative to that among control-treated NHFs (4-fold),
which indicates increased permissiveness to rAAV transduction.
The level did not reach that observed with E1B55k/E4orf6-treated
NHFs. The reason for this is unclear, but the different genetic
backgrounds (ATLD2 and NHF cells are derived from patient
fibroblasts and not isogenic) and, possibly, the upregulation of
compensatory pathways in ATLD2 cells may play a role. No en-
hancement was observed in the presence of E1B55k/E4orf6 (Fig.
2B). This finding indicates that the enhancement of gene expres-
sion from rAAV by E1B55k/E4orf6 is mediated largely through
removal of the block imposed by MRN.
The mechanism through which MRN inhibits AAV is not
known, but it affects the transduction of single-stranded vectors
prior to completion of second-strand DNA synthesis (16, 35, 36).
The pervading model predicts that MRN blocks AAV transduc-
tion at the step of second-strand DNA synthesis. The primary
evidence for this model is an increase in the completion of double-
stranded DNA genomes in the presence of E1B55k/E4orf6 (35,
36). However, this result cannot exclude the possibility that MRN
FIG 2 Enhancement of transduction of single-stranded and self-complemen-
tary AAV vectors upon degradation of MRN by E1B55k/E4orf6. (A) NHFs
were transduced with vectors expressing E1B55k and E4orf6 or luciferase, as a
control. Total cellular protein was prepared and analyzed for the levels of the
Mre11 and Nbs1 proteins, components of the cellular MRN complex, by SDS-
PAGE and immunoblotting. Detection of -actin served as a loading control.
(B and C) Effect of E1B55k/E4orf6 on transduction of single-stranded and
self-complementary CMV-GFP reporter vectors, respectively, in normal and
Mre11-deficient fibroblasts. NHFs and ATLD2 cells were pretreated to express
E1B55k/E4orf6 or luciferase and secondarily transduced with an ssCMV-GFP
or scCMV-GFP reporter vector. The level of fluorescence was measured by
flow cytometry, and the bar graph shows the percentage of cells positive for
GFP. Error bars represent standard deviations. (D) Forms of single-stranded
and self-complementary AAV genomes in E1B55k/E4orf6- and luciferase-
treated NHFs. AAV genomes were isolated from NHFs by a modified Hirt
extraction method and detected by Southern blotting. Radiolabeled probe was
generated using the GFP-coding sequence as the template. Blots were detected
by storage phosphor imaging and quantitated using ImageQuant software.
Molecules that correspond in size to that of the ssCMV-GFP vector (3,381 bp)
single-stranded and duplex forms and the scCMV-GFP vector (2,185 bp) du-
plex form were detected. The marker is a linear restriction product (3,091 bp)
containing all of the ssCMV-GFP vector genome except the ITRs. *, P 	 0.05;
n.s., not significant.
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blocks transduction at a step prior to second-strand DNA synthe-
sis. To resolve this question, we tested whether degradation of
MRN by E1B55k/E4orf6 enhances an rAAV vector that does not
require DNA synthesis for gene expression. The genome of self-
complementary AAV (scAAV) vectors has a central defective ITR
flanked by complementary arms of the expression cassette and
wild-type ITRs on the ends (55). These molecules can self-anneal
immediately upon release into the nucleus and do not require
DNA synthesis for expression of the transgene. As a result, scAAV
vectors have significantly increased transduction compared with
single-stranded AAV (ssAAV). Using the method described
above, NHFs and ATLD2 cells were pretreated for expression of
E1B55k/E4orf6 or luciferase prior to secondary transduction with
scCMV-GFP at a dose of 2,500 vg/cell (which produced 1 to
10% GFP-positive cells among the luciferase-treated controls).
Similar to the result obtained with ssCMV-GFP, the percentage of
cells positive for GFP was increased (
5-fold; P 	 0.05) among
NHFs expressing E1B55k/E4orf6 compared with that among
NHFs expressing luciferase (Fig. 2C). Again, the effect was not
observed in ATLD2 cells.
To evaluate rAAV DNA synthesis, vector genomes were recov-
ered from NHFs by a modified Hirt extraction method and ana-
lyzed by Southern blotting with a GFP-specific probe. Analysis of
cells receiving ssCMV-GFP revealed an increase in the number of
molecules that migrate near the position of the double-stranded
vector genome (3,382 bp), which is indicated by a marker for the
vector genome produced by restriction of the vector plasmid (Fig.
2D). Migration to this position is indicative of molecules that have
completed second-strand synthesis. The level of these double-
stranded genomes was increased 3-fold in cells expressing
E1B55k/E4orf6 (31  13 molecules/cell) compared with that in
cells expressing luciferase (12  8 molecules/cell), when measured
by densitometric analysis. In contrast, the level of total cell vector
genomes remained similar in both treatments (93%  9%). Anal-
ysis of cells receiving scCMV-GFP revealed molecules that migrate
at a position indicative of the self-annealed duplex genome
(2,305 bp) (Fig. 2D). No species with a molecular weight higher
than this were observed. Similar to the findings for cells receiving
ssCMV-GFP, the level of total cell vector genomes was similar in
both treatment groups (112%  23%).
These data demonstrate that the mechanism of MRN inhibi-
tion affects both ssAAV and scAAV vectors. Thus, inhibition can
occur independently of the requirement for second-strand DNA
synthesis.
Inhibition of rAAV by MRN takes place posttrafficking to the
nucleus. The observation that the degradation of MRN with
E1B55k/E4orf6 enhances both ssAAV and scAAV vectors prompted
investigation of steps in transduction prior to second-strand DNA
synthesis. Beginning with viral entry, we assessed whether steps
early in transduction were impeded by MRN. Vectors encapsi-
dated with different AAV serotype capsid proteins utilize different
cell surface receptors for binding and entry (56). To test whether
the effect of MRN occurs at these early steps, HeLa cells were
treated to express E1B55k/E4orf6 or luciferase (2,000 vg/cell total)
and subsequently transduced with rAAV vectors encapsidated
with the serotype 1, 3, 4, 5, 6, 8, or 9 capsid protein (1,000
vg/cell). Each vector carried the same ssCMV-GFP expression
cassette present in the AAV serotype 2 capsid used in the assays
whose results are presented in Fig. 1 and 2. The level of trans-
duction of all serotypes was increased in the presence of
E1B55k/E4orf6 compared with that in control cells, indicating
that all were subject to inhibition by MRN independently of the
surface receptor (Fig. 3A).
Subsequent to binding and entry, AAV is transported via an
endocytic pathway to the perinuclear region, where it escapes the
endosome and shuttles to the nucleus. This process includes many
steps but can be assessed by direct visualization of labeled virus
particles (53). To determine whether degradation of MRN affects
this transport, the intracellular localization of ssCMV-GFP la-
beled with the fluorochrome Cy5 was visualized at 6 h postrans-
duction in HeLa cells pretreated to express E1B55k/E4orf6 or lu-
ciferase (Fig. 3B). This time point was chosen because previous
findings indicated that 25% of rAAV particles have reached the
nucleus at 6 h postransduction and we expected particles to be
distributed across all steps of transport leading up to nuclear entry
(53). Upon visualization, the distribution of Cy5-ssCMV-GFP
was similar in cells expressing E1B55k/E4orf6 or luciferase and
typified the pattern previously reported for rAAV. Viral particles
appeared across the cytoplasm but were concentrated at a perinu-
clear site in the cell. Trafficking of rAAV has been shown to involve
the microtubule network, and this perinuclear site colocalizes
with the microtubule organization center (53). We did not ob-
serve a relocalization of the vector to suggest that trafficking was
significantly altered in a way that might account for the 
10-fold
increase in transduction. Instead, these data suggest that the
mechanism of inhibition of rAAV by MRN occurs posttrafficking
to the nucleus.
MRN inhibits the transduction of rAAV vectors indepen-
dently of several key downstream DNA damage response fac-
tors. The roles of the MRN complex include sensing of DNA dam-
age and activation of downstream signaling kinases, which in turn
initiate DDR (18, 19, 57). One of the primary targets for activation
by MRN, ATM kinase, has previously been shown to limit the
transduction of both ssAAV and scAAV vectors (58, 59). Thus, it is
possible that inhibition of rAAV by MRN is mediated through
downstream signaling and/or DNA repair factors. To determine if
this is the case, we tested whether the degradation of MRN by
E1B55k/E4orf6 results in the increased transduction of rAAV in a
panel of cell lines mutated for downstream signaling and repair
factors. The cell lines tested were deficient for key signaling ki-
nases, ATM and ATR, as well as repair factors Bloom’s syndrome
helicase (BLM), which is involved in HR repair; Werner’s syn-
drome helicase (WRN) and DNA-PKcs, which are involved in
NHEJ repair; and CSA, which is involved in nucleotide excision
repair (NER) (48, 49, 60–63). As in the assay whose results are
presented in Fig. 1, cells were pretreated to express E1B55k/E4orf6
or luciferase and subsequently transduced with the ssCMV-GFP
or scCMV-GFP reporter vector. The dose of vector used with each
cell line was selected to produce 1 to 5% GFP-positive cells
among control cells expressing luciferase. GFP expression was
measured at 24 h by flow cytometry. An increase in the percentage
of cells positive for GFP was observed with both vectors in all cell
lines when E1B55k/E4orf6 was expressed compared to the per-
centage observed when the luciferase control was expressed (Fig.
4). Thus, inhibition of rAAV is intact in each of these cell lines and,
therefore, independent of the mutated protein. Differences in the
scale of the effect were observed between several of the cell lines.
Cell lines defective for ATM, ATR, and WRN exhibited increases
in transduction of 3- to 5-fold for the scCMV-GFP vector and
5- to 8-fold for the ssCMV-GFP vector. In contrast, cell lines
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defective for BLM, DNA-PKcs, and CSA exhibited a scale of in-
crease more similar to that observed with normal fibroblasts: 8-
to 9-fold for scCMV-GFP and 10- to 15-fold for ssCMV-GFP.
The ability to draw conclusions from these differences is compli-
cated by the fact that the cell lines are not isogenic and subject to
different genetic backgrounds, which may modify the scale of the
effect. However, it is worth noting that ATM and ATR have been
shown to negatively affect gene expression from rAAV. The re-
duced effect of MRN in cell lines deficient for these factors may
reflect a contribution of ATM and ATR. Interestingly, our results
indicate that WRN may make a similar contribution to the inhi-
bition of gene expression from rAAV.
DNA binding activity appears to be more important than the
nuclease activity of Mre11 for inhibition of rAAV by MRN. The
finding that the mechanism of inhibition of rAAV transduction by
MRN is independent of downstream signaling and repair factors
turned our attention to the activities of the complex itself. Several
functions of the MRN complex can be attributed to subunit pro-
teins and, in some cases, distinct domains mapped within those
proteins. Two critical activities, DNA binding and nuclease activ-
ities, have been linked to defined domains on the Mre11 protein
(Fig. 5A) (19, 51, 52). In order to evaluate whether inhibition of
rAAV requires either of these activities, vector transduction was
evaluated in the presence of specific mutations in these domains.
For comparison with isogenic wt controls, we were interested in
studying these mutations in the context of fibroblasts derived
from transgenic mouse cell lines (MEFs), so we first tested for
conservation of MRN inhibition of rAAV in mouse cells. To do
FIG 3 Effect of degradation of MRN on early steps in transduction of AAV. (A) HeLa cells were pretreated to express E1B55k/E4orf6 or luciferase (2,000 vg/cell
total) and subsequently transduced with AAV vectors encapsidated with the capsid of the indicated serotype (10,000 vg/cell). Each vector packages the same
genome (CMV-GFP) but differs in the cell surface receptor used (indicated below the graph). Expression of GFP was quantified by flow cytometry. The
differences between E1B55k/E4orf6- and luciferase-treated samples were statistically significant (P 	 0.05) for all serotypes. ND, not determined. (B) HeLa cells,
pretreated as described in the legend to panel A, were subsequently transduced with the ssCMV-GFP vector encapsidated with the serotype 2 capsid protein and
conjugated with the fluorophore Cy5 (1,000 vg/cell). At 6 h postransduction with the labeled vector, cells were fixed and mounted onto slides. Cy5 and GFP were
visualized directly by fluorescence microscopy. Nuclei were detected by DAPI staining. The perinuclear accumulation of Cy5 label is indicated (arrows). Error
bars represent standard deviations.
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this, the transduction of scAAV-GFP was compared in MEFs car-
rying an A-to-T substitution at nucleotide 1894 of the mouse
Mre11 gene (50, 64). This mutation results in a 75-amino-acid
truncation of the protein and is analogous to human ATLD1 and
ATLD2 mutations (a C-to-T substitution at nucleotide 1897). Ex-
pression of GFP was increased 
2-fold (P 	 0.05) in the ATLD1
cells compared with that in the wt controls (Fig. 5B). The degree of
the effect was not as great as that observed in human cells, but it
confirms Mre11 inhibition of rAAV in mouse cells.
To assess the contribution of the functional domains of Mre11,
transduction of rAAV was measured in MEFs with a mutation in
the glycine-arginine-rich (GAR) motif within the DNA binding
FIG 4 Effect of degradation of MRN on transduction of AAV in cell lines deficient for DNA damage signaling and repair factors. Cell lines defective for ATM
(AT), ATR (GK41), BLM (AG06040), WRN (AG00780), DNA-PKcs (M059J), or CSA (AG05012) were tested for enhancement of AAV transduction upon
degradation of MRN by E1B55k/E4orf6. Cells were pretreated to express E1B55k/E4orf6 or luciferase and subsequently transduced with ssCMV-GFP or
scCMV-GFP reporter vector. The amount of vector used (vg/cell) was determined for each cell line, and 1 to 10% GFP-positive cells were produced among
luciferase-treated control cells. GFP fluorescence was measured by flow cytometry, and the percentage of cells positive for GFP was determined. The fold change
() in the percentage of GFP-positive cells was calculated by dividing the percentage of GFP-positive cells among E1B55k/E4orf6-treated cells by the percentage
of GFP-positive cells among luciferase-treated cells. Error bars represent standard deviations. The fold difference between E1B55k/E4orf6- and luciferase-treated
samples was statistically significant (P 	 0.05), unless otherwise indicated. ND, not determined; n.s., not significant.
FIG 5 Role of the functional domains of the Mre11 protein in inhibition of transduction of AAV. (A) Schematic of the spatial arrangement of functional domains
on the Mre11 protein (706 amino acids). The nuclease domain is comprised of five motifs located near the amino terminus of the protein and includes histidine
129, which is required for nucleolytic activity. The DNA binding domain is located near the carboxyl terminus and includes a glycine-arginine-rich (GAR)
domain, which is a preferred site of protein methylation. The positions of the H129N and RK mutations are indicated. (B) Transduction of MEFs deficient for
Mre11. MEFs (ATLD1 cells) carrying a mutation (premature stop codon) that mimics the human ATLD2 mutation (Fig. 2) and isogenic wt controls were
transduced with the scCMV-GFP reporter vector at a dose of 10,000 vg/cell. Cells were collected at 24 h postransduction, and the percentage of cells positive for
GFP was measured by flow cytometry. (C) Mre11RK/RK MEFs, which have the arginine residues of the GAR motif in the DNA binding domain replaced by lysines,
and isogenic wild-type (Mre11/) controls were treated as described in the legend to panel B. (D) Mre11Cond/H129N MEFs have an asparagine substituted for the
histidine at amino acid position 129. This mutation is embryonic lethal and is carried in the presence of a conditional wild-type allele. The phenotype of the
mutant allele is exposed by Cre-mediated excision of the conditional allele. Mre11Cond/H129N MEFs, as well as wt (Mre11Cond/) and knockout (Mre11Cond/)
controls, were transduced with the Ad-Cre vector at 2,000 (1) or 8,000 (4) particles/cell to remove the conditional allele. After 96 h, cells were transduced
with the scCMV-GFP vector. The percentage of cells positive for GFP fluorescence was measured by flow cytometry 24 h after delivery of the reporter vector. *,
P 	 0.05; n.s., not significant.
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domain of Mre11 (51). GAR motifs are preferred sites of methyl-
ation by protein arginine N-methylation (PRMT) enzymes (65).
In the mutant Mre11RK, nine arginine residues of the Mre11 GAR
motif are replaced by lysine. Yu et al. (51) described the interac-
tion between the mutant protein and MRN counterparts Rad50
and Nbs1 and assembly into foci in response to DNA damage.
Defects in nuclease activity, DNA binding, ATR/Chk1 activation
and signaling, and, to a small degree, class switch recombination
(CSR) were reported. ATM/Chk2 activation and signaling were
determined to be intact in the presence of this mutation. Trans-
duction of this cell line with scAAV-GFP resulted in an increase in
the level of expression of GFP of 2.5-fold (P 	 0.05) compared
with that by the isogenic wt controls (Fig. 5C), similar to the find-
ings for ATLD mutant MEFs. Thus, one or more of the activities
defective in the Mre11RK mutant contributes to inhibition of
rAAV transduction.
The mutant H129N substitutes a residue critical for the nu-
clease activity of Mre11 (52). Amino acid H129 is responsible for
stabilizing the scissile phosphate of the DNA backbone during
nucleotide excision. Mutation of this residue is embryonic lethal
in mice but is maintained in the presence of a conditional wt allele
in Mre11Cond/H129N MEFs. Excision by Cre recombinase exposes
the mutant phenotype. Buis et al. (52) determined that the
Mre11H129N protein is stably expressed, interacts with Rad50 and
Nbs1, and assembles in foci at sites of DNA damage. This mutant
protein was found to be defective in nuclease activity, ATR/Chk1
activation and signaling, and homologous recombination. Its
roles in DNA binding and ATM/Chk2 activation and signaling
were intact. To test for inhibition of rAAV, Mre11Cond/,
Mre11Cond/, and Mre11Cond/H129N MEFs were treated with Ad-
Cre (2,000 or 8,000 particles/cell) in order to excise the condi-
tional allele. The E1 genes are deleted in the Ad5-CMV-Cre vector
used for this purpose, and the E1B55k/E4orf6 complex is not in-
tact in this vector. Though this vector expresses E4orf6, this pro-
tein alone is insufficient for the degradation of MRN and enhance-
ment of rAAV (data not shown) (16). Cells were secondarily
transduced with scCMV-GFP, and transgene expression was mea-
sured by flow cytometry (Fig. 5D). The level of GFP expression
was increased 4-fold and 7-fold (P 	 0.05) with treatment of
2,000 and 8,000 particles/cell of Ad5-CMV-Cre, respectively, in
the Mre11/ control ( indicates removed conditional allele),
consistent with the loss of MRN inhibition. No increase was ob-
served in Mre11/ or Mre11/H129N cells treated with the lowest
dose of Ad5-CMV-Cre. At the highest dose of Ad-CMV-Cre
tested, 8,000 particles/cell, a statistically significant (P 	 0.05)
increase was observed in Mre11/H129N cells, but the increase
(	1.5-fold) was less than that observed with the loss of Mre11
(Mre11/) or mutation of the DNA binding domain (Mre11RK/
RK, 2.5-fold). These data reveal that inhibition of rAAV by MRN
correlates with DNA binding ability more than the nuclease activ-
ity of Mre11 does. Additionally, the results corroborate the find-
ings of analysis of human cell lines, in which inhibition was inde-
pendent of DNA damage factors, including ATM and ATR
kinases.
Inhibition of rAAV by MRN is independent of the sequence
and host species of the ITR. The results presented above indicate
that MRN inhibition of rAAV affects the vector genome specifi-
cally and not a plasmid template for expression (Fig. 1D) and
requires the DNA binding properties of Mre11. Consistent with
this, previous studies have provided evidence for a direct physical
interaction between MRN and the AAV genome, possibly medi-
ated through the terminal ITR structure. AAV genomes coprecipi-
tate with Mre11 from cell lysates, and the electromobility of an
oligonucleotide representing the AAV ITR is shifted in the pres-
ence of the Mre11 and Nbs1 proteins in vitro (16, 27). We wanted
to determine if a change to the sequence or structural features of
the ITR affects MRN inhibition of rAAV. Our group has described
ITRs altered in sequence and structure from the serotype 2 ITR
that retain the replication and packaging function (43, 66). The
ITR of serotype 5 AAV shares only 57% nucleotide sequence
identity with that of AAV2 and also differs in the spacing of ter-
minal and nicking stem-loop structures and overall length (Fig.
6A). Mutants ITR25NS and ITR52SNS are hybrids of the
AAV2 and AAV5 ITRs, respectively, in which the relative position
of the spacer region, the terminal stem-loop, and the nicking
stem-loop, as well as the sequence of the ITR, has been altered.
Vectors carrying these ITRs packaging the CMV-GFP expression
construct were evaluated for relative transduction efficiency as
well as the level of enhancement upon degradation of MRN by
E1B55k/E4orf6 in NHFs (Fig. 6B). Each of these vectors exhibited
a reduced transduction efficiency relative to that of wild-type
AAV2 ITR in cells expressing the luciferase control (11-fold for
ITR25NS, 5-fold for ITR52SNS, and 4-fold for ITR of
AAV5; P 	 0.05) at a dose of 10,000 vg/cell. However, the level of
transgene expression from vectors carrying ITR25NS and
ITR52SNS increased 55-fold and 26-fold, respectively, to be
near that from vectors carrying ITR2 (within 1.3-fold) in cells
expressing E1B55k/E4orf6 (Fig. 6C). The transduction efficiency
of the vector carrying ITR5 increased 8.9-fold so that it was only
within 2.7-fold of that of the vector carrying ITR2. Thus, the
hybrid ITRs experience a greater level of enhancement than either
of the wild-type ITRs.
To determine if inhibition by MRN is specific for human AAV
serotype ITRs, we developed a vector that has the CMV-GFP ex-
pression cassette substituted into snake AAV. This vector carries
snake AAV ITR sequences, which have only 50% nucleotide
sequence identity with serotype 2 or 5 ITRs. This vector could be
replicated and packaged in HEK293 cells expressing AAV2 and
snake AAV Rep and Cap proteins, as well as Ad helper proteins.
Transduction of NHFs, pretreated to express E1B55k/E4orf6 or
luciferase (2000 vg/cell total), with snake ITR revealed activity
similar to that of the AAV5 ITR vector. Expression of GFP was
increased 
10-fold in cells expressing E1B55k/E4orf6 compared
to that in cells expressing luciferase. This indicates that inhibition
of rAAV by MRN is not specific to human serotype ITRs but can
be generalized to ITRs of different species.
DISCUSSION
It is well established that cellular DDR networks, made up of sen-
sory, signaling, and repair factors, play a central role in the per-
missiveness of a cell to viral infection (7, 17). Factors of these
pathways, which normally function in maintenance of the cellular
genome, adopt auxiliary roles in response to invading genetic ma-
terial. The complex made up of Mre11, Rad50, and Nbs1 (MRN)
is critical in this struggle between pathogen and host. In this study,
we investigated the mechanism of MRN inhibition of gene expres-
sion from recombinant AAV. Recombinant AAV vectors have had
AAV genes and promoters removed and, instead, contain reagents
currently in clinical development. Thus, the mechanism in ques-
tion has high therapeutic relevance.
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The mobilization of Ad proteins E1B55k and E4orf6 in rAAV
vectors allowed study of the effect of transient degradation of
MRN on secondary rAAV transduction in human and mouse fi-
broblast cell lines, which are refractory to other methods of gene
delivery (e.g., transfection of plasmid DNA and transduction of
lentivirus). We found that delivery of E1B55k and E4orf6 on sep-
arate vectors was efficient enough to reach 25% of HeLa cells
and 
50% of NHFs at the doses used (Fig. 1C and 2B) and repro-
duces the mechanism of enhancement of wt AAV and rAAV re-
ported in previous studies (16, 35, 36). Gene expression from
rAAV was increased in both of these cell types: 5-fold in HeLa
cells and 10-fold in NHFs. The levels of MRN proteins Mre11
and Nbs1 were reduced with treatment with E1B55k/E4orf6, in-
dicating degradation of this complex, and completion of second-
strand DNA synthesis was increased with an ssAAV vector in
NHFs (Fig. 2A and D). With the ability to track this effect in
fibroblasts, we were also able to demonstrate that enhancement of
gene expression from rAAV is not observed in patient-derived
ATLD2 cells, which are deficient for Mre11 and highly permissive
to transduction (Fig. 2B). This provides direct evidence that the
effect of E1B55k/E4orf6 on rAAV is mediated primarily through
the degradation of MRN and removal of the inhibition imposed
by this complex.
The pervading model for this mechanism of inhibition is that
MRN inhibits rAAV by blocking second-strand DNA synthesis.
The primary evidence for this is the observation that double-
stranded forms of ssAAV genomes are increased with the degra-
dation or knockdown of MRN (16, 35, 36). Using expression of
E1B55k/E4orf6 as a tool to track inhibition by MRN, we tested
whether double-stranded rAAV (scAAV) vectors, which do not
require second-strand DNA synthesis for gene expression, are en-
hanced in a manner similar to that for ssAAV vectors. Our results
indicate that MRN inhibits both ssAAV and scAAV (Fig. 2C).
Southern blotting to detect vector genomes revealed that, while
conversion of ssAAV to the duplex form is increased, scAAV ge-
nomes appear in duplex form independently of the degradation of
MRN (Fig. 2D). Additionally, higher-molecular-weight species
were not detected. These findings are in contrast to the expected
result that only ssAAV vectors would be affected if inhibition by
MRN were the result of a block to DNA synthesis exclusively.
Instead, we can conclude that at least part of the mechanism of
inhibition precedes second-strand synthesis and is common to
single- and double-stranded templates.
Eliminating a block to second-strand DNA synthesis impelled
us to explore other possible mechanisms of inhibition of rAAV by
MRN. Inhibition was not observed with the CMV-GFP expression
cassette when delivered in the form of a transfected plasmid DNA
template, which did not display an increase in gene expression
upon degradation of MRN (Fig. 1D). Thus, the possibility of an
effect on the promoter, transport of the message, or translation of
the protein can be excluded. Testing steps in transduction as early
as cell receptor binding and entry, we found evidence that inhibi-
tion is independent of cell receptor usage (Fig. 3A) and does not
dramatically alter intracellular trafficking of the capsid (Fig. 3B).
Therefore, the mechanism of inhibition appears to take place in
the nucleus posttrafficking, which is consistent with the known
roles of MRN in DNA damage signaling and repair.
In response to sensing damage to the cellular genome, one
primary function of MRN is initiation of damage signaling and
activation of downstream repair networks (24–26). Previous stud-
ies have indicated that signaling kinases ATM and ATR, the pri-
mary targets of activation by MRN, can inhibit the transduction of
AAV (58, 59). Similarly, ATM is not required for the concatena-
tion of the Ad genome, observed when MRN is intact, but does
contribute to the inhibition of gene expression from this virus (32,
67). We investigated whether inhibition of rAAV by MRN in-
volves downstream damage signaling and repair by testing for
enhancement with E1B55k/E4orf6 in cell lines deficient for several
FIG 6 Effect of degradation of MRN on AAV vectors with mutant or nonhu-
man ITRs. (A) Schematic of wild-type and mutant ITRs. The vectors used in
this experiment were flanked by the human AAV serotype 2 ITR (TR2), the
human AAV serotype 5 ITR (TR5), transverse chimeras of these two serotypes
(TR25NS and TR52SNS), or serpentine AAV ITR (TRSn). (B) Level of
vector transduction. NHFs were pretreated to express E1B55k/E4orf6 or lucif-
erase (20,000 vg/cell total) and secondarily transduced with ssCMV-GFP re-
porter vectors (10,000 vg/cell) flanked by the indicated ITR. The percentage of
cells positive for GFP was measured by flow cytometry. Statistical comparison
between TR25NS, TR52SNS, or TR5 and TR2 was performed. *, P 	 0.05.
(C) Fold change in the percentage of cells positive for GFP.
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DDR factors. Cell lines deficient for ATM and ATR, as well as
Bloom’s syndrome helicase (BLM; which participates in the HR
and NHEJ pathways), Werner’s syndrome helicase (WRN; which
participates in the NHEJ pathway), DNA-PKcs (which partici-
pates in the NHEJ pathway), and CSA (which participates in
NER), were assessed. These cell lines were chosen because the
mutant factors participate in three separate pathways of DNA
damage repair, HR, NHEJ, and NER. In all cell lines, expression of
E1B55k/E4orf6 led to the enhancement of transduction of rAAV,
indicating that the factors tested are not required for inhibition
(Fig. 4). Interestingly, though an increase in the fold change in the
percentage of GFP-positive cells of a scale similar to that in NHFs
was observed in BLM-, DNA-PKcs-, and CSA-deficient cell lines,
enhancement was not as great in cell lines deficient for ATM, ATR,
and WRN. Given that kinases ATM and ATR are known to nega-
tively impact AAV, it is possible that the reduced effect in these cell
lines reflects a partial contribution of these factors. WRN has not
previously been tested for involvement in rAAV transduction.
Further testing will be required to determine if this factor does, in
fact, play an inhibitory role. Together, these findings indicate that
inhibition of rAAV by MRN is not dependent on several key fac-
tors of DNA damage repair signaling. However, we cannot elimi-
nate the possibility that other damage response factors in these
pathways play a role.
A second possibility for the mechanism of inhibition is degra-
dation of incoming rAAV genomes directly by MRN. Mre11 pos-
sesses phosphoesterase and DNA binding domains, and in puri-
fied form it exhibits endo- and exonuclease activity and interacts
with ssDNA and double-stranded DNA substrates (68–70). We
tested whether either of these functional domains contributes to
inhibition of rAAV. Analysis of the MEF lines with mutations in
the specific activities of Mre11 demonstrated that the nuclease
domain of MRN makes only a minor contribution to inhibition
(Fig. 5D). This is similar to the observation that the nuclease ac-
tivity of Mre11 is not required for inhibition of adenovirus (71).
Additionally, quantification of vector genomes by densitometric
analysis of DNA from Southern blots and separately by quantita-
tive PCR revealed similar copy numbers between enhanced and
nonenhanced cultures (Fig. 2D and data not shown). In contrast,
the DNA binding ability appears to make a greater contribution to
inhibition of rAAV (Fig. 5C). It would be interesting to look at
factors involved early during MRN binding to DNA. MdcI is
thought to play a role in loading MRN onto a DNA substrate.
Though this factor is not essential for MRN interaction and inhi-
bition of adenovirus, it is possible that MdcI plays a role in loading
MRN onto the AAV genome (72). Together, these results argue
against a mechanism of direct degradation but corroborate previ-
ous evidence for an interaction between MRN and the AAV ge-
nome (16, 27).
Evidence from this and previous studies suggests that the DNA
binding ability of MRN is important for the mechanism of inhi-
bition. Hairpin secondary structures and double-strand-to-sin-
gle-strand conversions, both present in the AAV ITR, are known
substrates for MRN (57). The in vitro binding of the Mre11 and
Nbs1 proteins of the MRN complex with an oligonucleotide rep-
resenting the AAV ITR has been demonstrated by gel shift (16).
Here, we tested whether the interaction of MRN with rAAV is
dependent on the sequence or structural arrangement of the ITR
or specific for human AAV ITRs. AAV serotype 2 and 5 ITRs share
only 57% nucleotide sequence identity. Additionally, we devel-
oped mutant ITRs, ITR25NS and ITR52SNS, with sequence
transversions between serotype 2 and 5 ITRs which are able to be
replicated and packaged (43). These ITRs rearrange the relative
position of the sequence and structural features within the two wt
ITRs. We found that vectors carrying these ITRs were all enhanced
for transduction upon degradation of MRN in the presence of
E1B55k/E4orf6 (Fig. 6). Interestingly, the baseline level of expres-
sion was reduced for the two transversion mutants, but the scale of
enhancement above the baseline was greater than that observed
with either parent serotype 2 or parent serotype 5. This suggests
that the extent of inhibition by MRN may be reduced with the
wild-type ITR relative to that with the mutant ITRs. Determina-
tion of whether this is the case will require testing for a direct
interaction of MRN with the ITR and comparative analysis be-
tween ITRs of different forms. In addition to the human serotypes,
we tested whether MRN inhibits a vector carrying a nonhuman
ITR derived from snake AAV, which shares only 50% nucleotide
sequence homology with either the serotype 2 or 5 ITR (45).
Transduction of this vector was enhanced to an extent similar to
that for the other wild-type ITRs. These findings indicate that the
effect of MRN is not dependent on the sequence or the strict po-
sitioning of the structural features within the ITR and is general-
ized to nonhuman ITRs. This is consistent with the known func-
tion of MRN in the cell, where it must respond to various forms of
DNA damage, independently of sequence. Unfortunately, this
likely means that inhibition by MRN cannot be circumvented
simply by modification of the ITR.
Ad proteins E1B55k and E4orf6 contribute pleiotropic func-
tions to productive infection of AAV. The ubiquitin ligase com-
plex formed by these factors targets cellular proteins, in addition
to MRN, for degradation, including the tumor suppressor p53 and
DNA ligase IV (73, 74). Though these other proteins play impor-
tant roles during productive AAV infection, they do not appear to
contribute to the inhibition of gene expression studied here. Mod-
ulation of p53 is important for regulating apoptosis and cell sur-
vival during AAV infection (75–77). However, mutants of E1B55k
incapable of degrading p53 retain the ability to degrade MRN and
enhance gene expression and replication of AAV, as shown suc-
cinctly by Schwartz et al. (16). Consistent with this, we observed
enhancement of rAAV upon expression of E1B55k/E4orf6 in cell
lines deficient for p53 (U2OS) (data not shown). DNA ligase IV
has been implicated in the integration of AAV genomes, but a role
in inhibiting gene expression or replication has not been reported
(78). A lack of enhancement of rAAV in ATLD2 cells (Mre11
deficient) indicates that if DNA ligase IV plays a role in this effect,
it is mediated through MRN. In addition to antagonizing these
cellular factors, E1B55k and E4orf6 have been shown to regulate
mRNA trafficking during Ad and AAV infection (79–83). Here,
we observed no enhancement of gene expression from a trans-
fected plasmid DNA carrying the vector genome or in cell lines
deficient for Mre11 (ATLD2) (Fig. 1D and 2B). This effect was
observed with non-AAV transcriptional elements [i.e., CMV or
the CBA promoter and simian virus 40 poly(A)], so it remains
possible that E1B55k/E4orf6 may enhance the expression of AAV
promoters or trafficking of viral mRNAs during wt AAV infection.
Thus, the effect that we were monitoring here appears to be me-
diated solely through degradation of MRN.
Together, the findings reported here greatly advance our un-
derstanding of the mechanism of inhibition of rAAV by the MRN
complex. We have demonstrated that the mechanism is not exclu-
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sively a block in second-strand DNA synthesis, as previously pro-
posed, but affects both single- and double-stranded rAAV ge-
nomes. We can also rule out a contribution of key downstream
DDR factors and degradation of the vector genome as the mech-
anism of inhibition of gene expression from rAAV by MRN. In-
stead, our results are consistent with a block to gene expression
after trafficking to the nucleus but prior to second-strand DNA
synthesis. The details of this mechanism are not resolved and re-
quire further investigation. However, we can propose several pos-
sible mechanisms based on our observations and previously re-
ported activities of MRN. One model is that interaction with MRN
sequesters the rAAV genome to a site within the nucleus inacces-
sible to cellular factors necessary for gene expression and DNA
synthesis (e.g., transcription factors). There is clear evidence for
the colocalization of MRN with incoming rAAV genomes soon
after transduction (27). Though the location of this interaction
has not been compared with that of transcription centers within
the nucleus, these sites may be exclusive. A second possibility is
that the nature of the interaction of MRN with the rAAV genome
poses a steric block to binding of transcription factors. There is
evidence that MRN binds the ITR structures present on the ends
of the rAAV genome (16). Binding at these structures would place
MRN upstream of and in proximity to the promoter for gene
expression. Additionally, the structure of MRN allows dimeriza-
tion between complexes formed at distal sites in the genome via a
hook domain in Rad50 (19, 21). During the response to damage to
the cellular genome, this function is thought to play a role in
maintaining proximity between sister chromatids to facilitate ho-
mologous recombination repair and in stabilizing replication fork
progression. In the context of interaction with the rAAV genome,
dimerization between MRN complexes bound at the ITR within
(cis) or between (trans) genomes may occur. The formation of
such structures, albeit speculative, may contribute to reduced
gene expression via steric hindrance or another mechanism.
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